Oral treatment patients receive oral imatinib mesylate. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy7

K562 Cells Philadelphia Chromosome Cell Line, Tumor Chromosomes, Human, Pair 9 Neoplastic Stem Cells Cells, Cultured Myeloid Progenitor Cells

Organisms2

Mice, Inbred BALB C Rats, Wistar

Diseases25

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Gastrointestinal Stromal Tumors Leukemia, Myeloid, Chronic-Phase Blast Crisis Hypereosinophilic Syndrome Hypopigmentation Gastrointestinal Neoplasms Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Philadelphia Chromosome Dermatofibrosarcoma Mastocytosis, Systemic Fibromatosis, Aggressive Leukemia, Myeloid, Accelerated Phase Disease Models, Animal Cowpox Lichenoid Eruptions Recurrence Neoplasm, Residual Primary Myelofibrosis Disease Progression Scleroderma, Systemic Histiocytoma, Malignant Fibrous Precursor Cell Lymphoblastic Leukemia-Lymphoma Fibrosis Graves Ophthalmopathy

Chemicals and Drugs38

Benzamides Piperazines Pyrimidines Fusion Proteins, bcr-abl Antineoplastic Agents Proto-Oncogene Proteins c-kit Protein Kinase Inhibitors Receptor, Platelet-Derived Growth Factor alpha Receptor, Platelet-Derived Growth Factor beta Proto-Oncogene Proteins c-abl Protein-Tyrosine Kinases Niridazole Enzyme Inhibitors Receptors, Platelet-Derived Growth Factor Pregnatrienes Thiazoles Proto-Oncogene Proteins c-sis Harringtonines Antiprotozoal Agents Interferon-alpha mRNA Cleavage and Polyadenylation Factors Ketones RNA, Messenger Furans Pyrroles Rifabutin Plant Extracts Hydroxyurea STAT5 Transcription Factor Platelet-Derived Growth Factor Stem Cell Factor Drug Combinations Indoles Anti-Bacterial Agents Organophosphonates Oncogene Proteins, Fusion Sulfones Antigens, CD34

Analytical, Diagnostic and Therapeutic Techniques and Equipment30

Treatment Outcome Administration, Oral Cytogenetic Analysis Remission Induction Drug Administration Schedule Drug Approval Disease-Free Survival Disease Models, Animal Double-Blind Method Injections, Intravenous Clinical Trials as Topic Administration, Topical Survival Analysis Antineoplastic Combined Chemotherapy Protocols Immunohistochemistry Drug Therapy, Combination Prognosis Treatment Failure Salvage Therapy In Situ Hybridization, Fluorescence Reverse Transcriptase Polymerase Chain Reaction Survival Rate Inhibitory Concentration 50 Infusions, Intravenous Follow-Up Studies Drug Evaluation, Preclinical Neoadjuvant Therapy Blood Cell Count Combined Modality Therapy Phytotherapy

Phenomena and Processes18

Drug Resistance, Neoplasm Genes, abl Philadelphia Chromosome Dose-Response Relationship, Drug Time Factors Apoptosis Cell Proliferation Phosphorylation Drug Synergism Mutation Gene Expression Regulation, Leukemic Biological Availability Chromosomes, Human, Pair 9 Inhibitory Concentration 50 Signal Transduction Drug Interactions Cell Survival Blood Cell Count

Disciplines and Occupations2

Cytogenetics Immunohistochemistry

Anthropology, Education, Sociology and Social Phenomena2

Drug Approval United States Food and Drug Administration

Information Science1

Health Care9

Treatment Outcome Disease-Free Survival Double-Blind Method Clinical Trials as Topic Survival Analysis United States Food and Drug Administration Treatment Failure Survival Rate Follow-Up Studies

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Information Science Health Care

Benzamides Piperazines Pyrimidines Treatment Outcome Leukemia, Myelogenous, Chronic, BCR-ABL Positive Gastrointestinal Stromal Tumors Fusion Proteins, bcr-abl Administration, Oral Antineoplastic Agents Proto-Oncogene Proteins c-kit Protein Kinase Inhibitors Receptor, Platelet-Derived Growth Factor alpha Leukemia, Myeloid, Chronic-Phase Receptor, Platelet-Derived Growth Factor beta Blast Crisis Drug Resistance, Neoplasm Genes, abl Hypereosinophilic Syndrome Cytogenetic Analysis Proto-Oncogene Proteins c-abl Protein-Tyrosine Kinases Hypopigmentation K562 Cells Gastrointestinal Neoplasms Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Philadelphia Chromosome Dose-Response Relationship, Drug Niridazole Remission Induction Enzyme Inhibitors Receptors, Platelet-Derived Growth Factor Time Factors Dermatofibrosarcoma Drug Administration Schedule Mastocytosis, Systemic Drug Approval Pregnatrienes Cell Line, Tumor Fibromatosis, Aggressive Thiazoles Proto-Oncogene Proteins c-sis Disease-Free Survival Harringtonines Leukemia, Myeloid, Accelerated Phase Antiprotozoal Agents Disease Models, Animal Cowpox Apoptosis Double-Blind Method Lichenoid Eruptions Injections, Intravenous Cell Proliferation Interferon-alpha Recurrence mRNA Cleavage and Polyadenylation Factors Phosphorylation Neoplasm, Residual Drug Synergism Clinical Trials as Topic Mutation Ketones Administration, Topical RNA, Messenger Mice, Inbred BALB C Gene Expression Regulation, Leukemic Cytogenetics Survival Analysis Antineoplastic Combined Chemotherapy Protocols Furans Immunohistochemistry Pyrroles Drug Therapy, Combination United States Food and Drug Administration Prognosis Rifabutin Treatment Failure Plant Extracts Salvage Therapy Biological Availability Primary Myelofibrosis Disease Progression Chromosomes, Human, Pair 9 In Situ Hybridization, Fluorescence Hydroxyurea Neoplastic Stem Cells STAT5 Transcription Factor Platelet-Derived Growth Factor Reverse Transcriptase Polymerase Chain Reaction Cells, Cultured Survival Rate Scleroderma, Systemic Histiocytoma, Malignant Fibrous Precursor Cell Lymphoblastic Leukemia-Lymphoma Stem Cell Factor Inhibitory Concentration 50 Drug Combinations Signal Transduction Myeloid Progenitor Cells Drug Interactions Infusions, Intravenous

No FAQ available that match "oral treatment patients receive oral imatinib mesylate"